N1-methylpseudouridine enhances immunogenicity of RNA/lipid nanoparticle vaccines targeting SARS-CoV-2 spike and the model antigen ovalbumin
The recent success of RNA/lipid nanoparticle (LNP)-based vaccine formulations in the clinic against SARS-CoV-2 and RSV has highlighted the potential of this platform. While RNA/LNP vaccines share the fundamental principle of using lipid nanoparticles to deliver RNA molecules into host cells to induce antigen expres...